The Zephyr® Endobronchial Valve is clinically-proven to improve lung function, exercise capacity, dyspnea and improve quality of life for patients with severe emphysema.1 The Zephyr Valve is the first endobronchial valve to receive approval from the FDA for patients with either heterogeneous or homogeneous emphysema and can be used to treat the upper and lower lobes of either lung. Zephyr Valve patients (over 25,000 globally) report significant improvements in breathing and often within weeks see an improvement in quality of life and the ability to do everyday tasks again.
1 Criner, G et al. Am J Resp Crit Care Med. 2018 Nov 1;198(9):1151-1164